Related Experiment Videos
Antithymocyte antiserum therapy in myasthenia gravis
Postgraduate Medical Journal
|January 11, 1976
Summary
Goat anti-human thymocyte antiserum globulin (ATG) showed therapeutic effects in most myasthenia gravis patients. Long-term follow-up revealed varying relapse rates after prolonged, low-dose intramuscular therapy.
Area of Science:
- Immunology
- Neurology
Background:
- Myasthenia gravis is a chronic autoimmune neuromuscular disease.
- Current treatments for myasthenia gravis have limitations.
Purpose of the Study:
- To evaluate the therapeutic efficacy of goat anti-human thymocyte antiserum globulin (ATG) in myasthenia gravis patients.
- To assess long-term outcomes and relapse rates following ATG therapy.
Main Methods:
- Ten myasthenia gravis patients received prolonged, low-dose intramuscular goat ATG.
- Therapeutic responses were monitored, and patients were followed for over 5 years.
Main Results:
- Eight out of ten patients exhibited varying degrees of therapeutic response to goat ATG.
- Long-term follow-up data on relapse rates were collected and analyzed.
Conclusions:
- Goat anti-human thymocyte antiserum globulin (ATG) demonstrates therapeutic potential in managing myasthenia gravis.
- Prolonged, low-dose ATG therapy can lead to sustained improvement in some patients, though relapse rates vary.